Gene therapy medication, Spinraza, provides improvements for patients with spinal muscular atrophy
Spinraza has provided significant improvements in cases with the next most severe form of the neuromuscular disease, spinal muscular atrophy (SMA), which affects children aged from 6 to 18 months.
“The effects are convincing, and this reinforces results from the earlier study,” says Mar Tulinius, Professor of paediatrics at Sahlgrenska Academy and chief medical officer at the Queen Silvia Children’s Hospital. the Swedish portion of the trial. Where Spinraza was administered for the most severe form of spinal muscular atrophy, SMA type 1, which afflicts children before they are six months old.
In more recent times the study involved SMA type 2, in which the illness occurs when children have learned to sit by themselves but have not yet begun to walk. As the muscles gradually weaken the children never stand upright on their legs and ultimately they need respirators to survive.
Approximately two out three children in the current study received Spinraza; one out of three received a placebo. Results of which have shown that the drug with the active substance nusinersen, which partly compensates for an inherited genetic error, altered the children’s condition.
Their ability to sit up straight, raise their hands, move by rolling around, etc., was improved by an average of four points on the scale used to measure changes in spinal muscular atrophy. At the same time, children in the placebo group regressed an average of 1.9 points on the scale.
“The natural progression is for the children to lose points on this scale. Although there are variations within the group, they are never destined to get better. The fact that strength and mobility increased in those who received the drug is really quite amazing,” Prof Tulinius said.
People with spinal muscular atrophy lack a protein that is required for the motor nerve cells in the spinal cord to function. If both parents are carriers, the likelihood that the child will get the disease is 25%.
Approximately 10 children in Sweden are diagnosed with SMA every year. The two most difficult variations, type 1 and 2, are covered by a recently issued recommendation from the Swedish Council for Novel Therapies (NT-rådet) of Sweden’s municipalities and county councils that under certain conditions and strict control, children should be offered treatment with Spinraza.
“Often, they say no, we can’t afford it, when it comes to expensive orphan drugs. But this one produces such good results that it is impossible to ignore,” says Prof Tulinius.
Source: European Pharmaceutical Review